Menu Display

Breadcrumb

Global Business Development

We’re accelerating our external innovation efforts – advancing differentiated science through bold partnerships with the shared ambition to improve patient lives.  

Innovation is a team sport. We show up in the world’s leading biotech ecosystems where new ideas take shape and where collaboration accelerates progress. 

At Daiichi Sankyo, we pursue science that strengthens our oncology leadership, complements our pipeline, and expands what’s possible through emerging platforms and research technologies. Rooted in disciplined scientific inquiry and a legacy of innovation, we bring cross-functional expertise, from bio-modalities and pharmacology to advanced data science, built on the deep capabilities shaped by our DXd ADC platform. 

We tailor collaboration models to the needs of each asset and partner, leveraging our global R&D network to connect potential partners with the right experts and help promising science move forward faster.

“Innovation doesn’t happen in isolation. We seek partners who share our commitment to advancing science with integrity, curiosity, and courage.”

–  Stu Mackey, Global Head of Business Development, Daiichi Sankyo

Scientific Areas of Interest

Advancing science together. Explore our scientific focus areas and learn more about our partnering priorities below.
    • Breast, Lung and Colorectal cancer assets in late preclinical and early clinical stage.
    • Tumor-specific antibody-related molecules, with interest in TME-specific activation and antibodies targeting novel, tumor-specific epitopes
    • T-cell engager technologies with enhanced efficacy / functionality versus current clinical-stage T-cell-targeted antibody therapeutics
    • Heterobifunctional protein degraders that:
      • Utilize E3 ligases other than CRBN, VHL, IAP, or MDM2
      • Employ novel degradation mechanisms independent of the ubiquitin proteasome system (UPS)
    • Therapeutic areas (seeking novel biology, research models and biomarkers) – examples below:
      • CNS: Alzheimer’s disease biology and models; ALS models
      • Cardiovascular & Metabolic: Heart failure biomarkers; disease stratification biomarkers
      • Immunology & Inflammation (e.g., IBD, SLE): Novel therapeutic targets and disease-specific binders
      • Fibrosis: Pulmonary fibrosis models; IPF digital biomarkers
      • Ophthalmology: Retinal disease targets and models
    • Innovative modalities and technologies:
      • AAV vector technologies
      • Non-viral vector technologies
      • Direct reprogramming (also known as transdifferentiation)
      • Ocular delivery technologies
      • Intracellular trafficking technologies
      • AI related technologies for therapeutic design or target identification 

Connected to What's Next

Our search & evaluation, transactions, alliance management, and strategic initiatives teams work closely within our Global Business Development organization to create a smooth, coordinated experience for partners from early discussions through long-term collaboration. Our approach is grounded in transparency, flexibility, and shared purpose, inspired by the Japanese principle of sanpo-yoshi: good for you, good for us, and good for patients.

With team members across Japan, the United States, Europe, and China and deep collaboration with our Research Institutes in Boston, Munich, and San Diego, we stay embedded in major innovation hubs around the world. These connections strengthen our ability to build strategic partnerships and accelerate promising science.

 

Tell us about your science.
Please submit your non-confidential licensing or alliance proposal for consideration

Transforming Science into Medicines

By uniting cutting-edge science and technology with a genuine interest in people, we develop high-quality, life-changing solutions for the patients of today and tomorrow with great care and unwavering dedication.